Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRN23 in adults with X-linked hypophosphatemia
NCT01571596Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Feb 2012
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of burosumab in X-linked hypophosphatemia (XLH), sponsored by Kyowa Kirin. Primary endpoints: Safety of Repeated SC Injections of KRN23 at 13.5 months and Efficacy of Repeated SC Injections of KRN23 at 13.5 months. Started Feb 2012; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT01571596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01571596.